Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-18T12:44:49.749Z Has data issue: false hasContentIssue false
  • English
  • Français

Trametinib for Painful Glomus Tumors in a Patient with Neurofibromatosis Type 1

Published online by Cambridge University Press:  31 March 2022

Seth A. Climans Open the ORCID record for Seth A. Climans [Opens in a new window] ,
Ronald C. Ramos Open the ORCID record for Ronald C. Ramos [Opens in a new window] ,
Dimitri J. Anastakis  and
Warren P. Mason
Seth A. Climans*
Affiliation:
Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of Oncology, London Health Sciences Centre, London, Canada
Ronald C. Ramos
Affiliation:
Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Division of Neurology, Hamilton Health Sciences, Hamilton, Canada
Dimitri J. Anastakis
Affiliation:
Division of Plastic and Reconstructive Surgery, Department of Surgery, Toronto Western Hospital, Toronto, Canada
Warren P. Mason
Affiliation:
Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
*
Corresponding author: Seth A. Climans, Department of Oncology, London Health Sciences Centre, 800 Commissioners Rd E London, Ontario, Canada, N6A 5W9. Email: seth.climans@lhsc.on.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

GlomangiomaNeurofibromatosis type 1Targeted chemotherapyPlastic surgeryNeuro-oncology
Type
Letter to the Editor: New Observation
Information
Canadian Journal of Neurological Sciences , Volume 50 , Issue 3 , May 2023 , pp. 477 - 478
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Seth A Climans and Ronald C Ramos contributed equally.

References

Ferner, RE, Gutmann, DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939–55.CrossRefGoogle ScholarPubMed
Stewart, DR, Sloan, JL, Yao, L, et al. Diagnosis, management, and complications of glomus tumors of the digits in neurofibromatosis type 1. J Med Genet. 2010;47:525–32.CrossRefGoogle ScholarPubMed
Harrison, B, Sammer, D. Glomus tumors and neurofibromatosis: a newly recognized association. Plast Reconstr Surg Glob Open. 2014;2:e214.CrossRefGoogle ScholarPubMed
Brems, H, Park, C, Maertens, O, et al. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res. 2009;69:7393–401.CrossRefGoogle ScholarPubMed
McDermott, EM, Weiss, A-PC. Glomus tumors. J Hand Surg. 2006;31:1397–400.CrossRefGoogle ScholarPubMed
Gross, AM, Wolters, PL, Dombi, E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430–42. DOI 10.1056/NEJMoa1912735.CrossRefGoogle ScholarPubMed
Selt, F, van Tilburg, CM, Bison, B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020;149:499–510.CrossRefGoogle ScholarPubMed
Falchook, GS, Lewis, KD, Infante, JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782–9.CrossRefGoogle ScholarPubMed